Methods for monitoring ELOVL2, KLF14 and PENK gene expression following treatment with vitamin C
First Claim
Patent Images
1. A method of detecting an expression level of ELOVL2, KLF14, and PENK in a first subject, comprising:
- a) administering to the first subject a therapeutically effective dose of vitamin C or its derivatives, metabolites, or pharmaceutically acceptable salts thereof for a first time period;
b) obtaining a sample from the first subject after the first time period; and
c) detecting the expression level of ELOVL2, KLF14, and PENK in the first subject by contacting the sample with one set and no more than one set of nucleic acid probes, wherein the one set of nucleic acid probes hybridizes to three markers and no more than three markers, wherein the three markers are ELOVL2, KLF14, and PENK and detecting binding between ELOVL2, KLF14, or PENK and the nucleic acid probes.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).
-
Citations
21 Claims
-
1. A method of detecting an expression level of ELOVL2, KLF14, and PENK in a first subject, comprising:
-
a) administering to the first subject a therapeutically effective dose of vitamin C or its derivatives, metabolites, or pharmaceutically acceptable salts thereof for a first time period; b) obtaining a sample from the first subject after the first time period; and c) detecting the expression level of ELOVL2, KLF14, and PENK in the first subject by contacting the sample with one set and no more than one set of nucleic acid probes, wherein the one set of nucleic acid probes hybridizes to three markers and no more than three markers, wherein the three markers are ELOVL2, KLF14, and PENK and detecting binding between ELOVL2, KLF14, or PENK and the nucleic acid probes. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. A method of detecting the expression level of a plurality of markers in a first subject, comprising:
-
a) administering to the first subject a therapeutically effective dose of vitamin C or its derivatives, metabolites, or pharmaceutically acceptable salts thereof for a first time period; b) obtaining a sample from the first subject after the first time period; and c) detecting the expression level of ELOVL2, KLF14, PENK, and one or more markers selected from the group consisting of FHL2, SMC4, SLC12A5, TEZM151A, TTF2, TRIM45, TRIM59, ACSS3, ARID5A, BLMH, BRD4, CD28, EPHX3, SLX1, BDNF, NDF, and GDNF in the first subject by; i) contacting the sample with two sets and no more than two sets of nucleic acid probes, wherein the first set of nucleic acid probes hybridizes to three markers and no more than three markers, wherein the three markers are ELOVL2, KLF14, and PENK and wherein the second set of nucleic acid probes hybridizes to at least one but no more than 19 markers selected from the group consisting of FHL2, SMC4, SLC12A5, TEZM151A, TTF2, TRIM45, TRIM59, ACSS3, ARID5A, BLMH, BRD4, CD28, EPHX3, RIN1, SLX1, BDNF, NDF, GDNF, and combinations thereof; and ii) detecting binding between ELOVL2, KLF14, or PENK and nucleic acid probes in the first set of nucleic acid probes and between one or more markers selected from the group consisting of FHL2, SMC4, SLC12A5, TEZM151A, TTF2, TRIM45, TRIM59, ACSS3, ARID5A, BLMH, BRD4, CD28, EPHX3, RIN1, SLX1, BDNF, NDF, and GDNF and nucleic acid probes in the second set of nucleic acid probes. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
Specification